Gennaro Pagano: Difference between revisions
(→Career) |
(→Career) |
||
| Line 21: | Line 21: | ||
=== Career === | === Career === | ||
2020-ongoing: Expert Medical Director & Group Leader | Roche Pharma Research & Early Development, Basel, Switzerland. | * 2020-ongoing: Expert Medical Director & Group Leader | Roche Pharma Research & Early Development, Basel, Switzerland. | ||
** Line management responsibility of 10+ direct reports including Medical Directors, Medical Directors Fellows, Senior Clinical Scientists, Clinical Scientists and Patient Partnership Directors; | |||
** Squad Lead of Parkinson’s disease Strategy; | |||
** clinical and scientific leadership of clinical expert teams for the development of drugs for Parkinson’s, Alzheimer’s, Neurodevelopmental and Sleep disorders, and Rare diseases; | |||
== External links == | == External links == | ||
Revision as of 16:05, 16 January 2023
Prof. Gennaro Pagano is a physician-neuroscientist and pharma medical director with over 10 years of experience in translational research and early clinical development. He holds a Doctor of Medicine, Master in Epidemiology, Doctor of Philosophy in Clinical Neuroscience, and has postdoctoral training in PET molecular imaging with a focus on genetics, preclinical, and prodromal Parkinson's disease. He has a h-index of 39 on Google Scholar, and has published over 100 peer-reviewed publications in the field of neurodegeneration (common and rare movement disorders, and dementia).[1]
Prof. Pagano currently works as an Expert Medical Director and Group Leader at Roche Pharma Research and Early Development in Switzerland and serves as also the Chair of the Medical Directors Fellowship program in Neuroscience and Rare disease (NRD). He is also Honorary Clinical Associate Professor in Neurology and Neuroimaging at the University of Exeter Medical School, and former Chair of Parkinson's Progressive Markers Initiative (PPMI) Partner Scientific Advisory Board.[2]
Before joining Roche, Gennaro was the Lily Safra Senior Clinical Fellow in Neurology and Research & Development Leader of the Neurodegeneration Imaging Group, Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience at the King’s College London. In this role, he designed, implemented and led several Phase 0, 1 and Phase 2 proof-of-concept trials, and published his research on peer-reviewed International journals, such as New England Journal of Medicine, Lancet Neurology, Movement Disorders, Brain, Neurology, Annals of Neurology, European Journal of Neurology, Journal Clinical Investigation among others.[3]
Education and career
Education
- 2019-2021: European Course Diploma in Pharmaceutical Medicine (ECPM) | University of Basel, Basel
- 2018-2020: Executive Master in Business and Administration (eMBA) | Quantic School of Business and Technology, US
- 2015-2018: Doctor of Philosophy in Clinical Neuroscience (PhD) | Institute of Psychiatry, Psychology & Neuroscience, UK
- 2010-2015: Residency in Geriatrics (first-in-class with honors) | Federico II University, Italy
- 2011-2012: Master in Epidemiology, Cochrane Systematic review and Meta-Analysis (MSc) | University of Milan, Italy
- 2003-2009: Medical School (first-in-class with honors) (MD) | Federico II University, Italy
Career
- 2020-ongoing: Expert Medical Director & Group Leader | Roche Pharma Research & Early Development, Basel, Switzerland.
- Line management responsibility of 10+ direct reports including Medical Directors, Medical Directors Fellows, Senior Clinical Scientists, Clinical Scientists and Patient Partnership Directors;
- Squad Lead of Parkinson’s disease Strategy;
- clinical and scientific leadership of clinical expert teams for the development of drugs for Parkinson’s, Alzheimer’s, Neurodevelopmental and Sleep disorders, and Rare diseases;
External links
Placeholder
